Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04638647 · ClinicalTrials.gov registry record · Phase 4
Secukinumab Open Label Roll-over Extension Protocol
A Phase 4 study of Autoimmunity, Inflammation, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT04638647 is a Phase 4 study of Autoimmunity, Inflammation that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 1,000 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT04638647, a Phase 4 study of Autoimmunity, Inflammation, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
Conditions Studied
Interventions
- BIOLOGICAL Secukinumab s.c. injection
Study Locations (20)
California
- Providence Medical Foundation - Fullerton
- Purushotham Akther and Roshan Kotha MD Inc - La Mesa
- Precn Comprehensive Clnl Rsch Solns - San Leandro
- Orrin Troum MD and Medical Associates - Santa Monica
- Inland Rheumatology Clinical Trials INC - Upland
- Medvin Clinical Research - Van Nuys
- Center for Rheumatology Research - West Hills
Florida
- Rheumatology Associates of South Florida - Boca Raton
- Homestead Assoc In Research Inc - Homestead
- IRIS Research and Development - Plantation
- Conquest Research - Winter Park
- FL Medical Clinic Orlando Health - Zephyrhills
Colorado
- Denver Arthritis Clinic - Denver
Illinois
- Willow Rheumatology Wellness - Willowbrook
Indiana
- Dawes Fretzin Clinical Rea Group - Indianapolis
Maryland
- Klein and Associates - Hagerstown
Michigan
- Ahmed Arif Medical Research Center - Grand Blanc
Nebraska
- Physician Research Collaboration - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2030-04-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04638647
The ClinicalTrials.gov registry entry for NCT04638647 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autoimmunity, Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Secukinumab s.c. injection is the first listed.
NCT04638647 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT04638647 about?
NCT04638647 is a clinical study titled "Secukinumab Open Label Roll-over Extension Protocol". The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
What is the current status of trial NCT04638647?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 1,000 participants. The study started on 2020-12-22. Estimated completion is 2030-04-04.
What conditions does trial NCT04638647 study?
This clinical trial studies the following conditions: Autoimmunity, Inflammation.
What interventions are being tested in trial NCT04638647?
The interventions under investigation include: Secukinumab s.c. injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT04638647?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04638647 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.